GlobeNewsWire
13 Jun 2026, 16:45 UTC · 14w ago
Verdict
Headline takes no side. We score GMAB +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Epcoritamab combined with R-mini-CHOP demonstrated a 93% overall response rate and 86% complete response rate in elderly patients with newly diagnosed DLBCL.
More positive than 99% of claims this week
Epcoritamab monotherapy achieved a 67% overall response rate and 58% complete response rate for elderly DLBCL patients ineligible for standard chemotherapy.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 92% of claims this week
Phase 2 data for epcoritamab monotherapy showed a median progression-free survival of 13.0 months with 62% of patients alive at 18 months.
More positive than 77% of claims this week
The safety profile for epcoritamab in elderly patients included a 71% rate of cytokine release syndrome (CRS) and 18% rate of ICANS.
More negative than 71% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company announced high response rates and positive clinical data for epcoritamab in elderly patients with DLBCL.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
48m ago
+38.1%
Price agrees with the score
$34.63 vs $25.08 close before publication (Jun 12) · not market-adjusted
GMAB chart →
